EyePoint plans to cut approximately 53% of workforce

• EyePoint will cut approximately 53% of its workforce and end its pivotal Phase 3 wet AMD trials early.
• Most job cuts are expected in the fourth quarter of 2026, with completion in the first half of 2027.
• The restructuring is expected to generate approximately $30 million in annualized savings, with about $9 million in employee separation charges.
• The move follows the Phase 3 LUCIA wet AMD study’s failure to meet its primary non-inferiority endpoint.
• Resources will shift to DURAVYU’s diabetic macular edema program, with pivotal Phase 3 results expected in the fourth quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190715PRIMZONEFULLFEED9848348) on October 19, 2026, and is solely responsible for the information contained therein.